Table 3 The relationships of the clinicopathological parameters as well as the expression of UGP2 and CFL1 in the PDC patients with their average survival time
Grouping | Number of cases (N) | Average survival (month) | Chi-square | P value |
|---|---|---|---|---|
Sex | ||||
Male | 61 | 9.98 (2–24) | 1.656 | 0.198 |
Female | 45 | 8.61 (2–21) | ||
Age | ||||
≤ 45 years old | 22 | 8.18 (3–19) | 2.144 | 0.143 |
> 45 years old | 84 | 9.73 (2–24) | ||
Degree of differentiation | ||||
Highly differentiated | 38 | 11.27 (3–24) | 17.786 | 0.000 |
Moderately differentiated | 35 | 9.74 (3–21) | ||
Poorly differentiated | 33 | 6.86 (2–14) | ||
Maximal diameter of the mass | ||||
≤ 3 cm | 13 | 13.46 (5–21) | 7.504 | 0.023 |
3–5 cm | 68 | 9.34 (2–22) | ||
> 5 cm | 25 | 7.40 (3–24) | ||
TNM stage | ||||
I | 11 | 16.46 (11–24) | 80.807 | 0.000 |
II | 42 | 11.37 (3–22) | ||
III | 37 | 7.14 (2–17) | ||
IV | 16 | 4.56 (2–8) | ||
Lymph node metastasis | ||||
No | 77 | 10.64 (2–24) | 27.120 | 0.000 |
Yes | 29 | 6.35 (2–12) | ||
Invasion of the surrounding tissue | ||||
No | 42 | 13.33 (5–24) | 46.949 | 0.000 |
Yes | 64 | 6.83 (2–17) | ||
UGP2 | ||||
− | 44 | 12.73 (5–24) | 33.912 | 0.000 |
+ | 62 | 7.10 (2–18) | ||
CFL1 | ||||
− | 50 | 12.28 (3–24) | 36.767 | 0.000 |
+ | 56 | 6.77 (2–18) | ||